Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EMERGENT BIOSOLUTIONS INC.

(EBS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/14/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
61.79(c) 61.57(c) 61.96(c) 63.12(c) 60.55(c) Last
810 073 862 526 459 278 555 982 2 015 652 Volume
-2.71% -0.36% +0.63% +1.87% -4.07% Change
More quotes
Financials (USD)
Sales 2021 1 800 M - -
Net income 2021 377 M - -
Net Debt 2021 71,2 M - -
P/E ratio 2021 8,81x
Yield 2021 -
Sales 2022 1 461 M - -
Net income 2022 200 M - -
Net cash position 2022 305 M - -
P/E ratio 2022 16,8x
Yield 2022 -
Capitalization 3 245 M 3 245 M -
EV / Sales 2021 1,84x
EV / Sales 2022 2,01x
Nbr of Employees 2 200
Free-Float 88,6%
More Financials
Company
Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two... 
Sector
Pharmaceuticals
Calendar
08/05Earnings Release
More about the company
Ratings of Emergent BioSolutions Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about EMERGENT BIOSOLUTIONS INC.
06/19MONDAY DEADLINE ALERT : The Schall Law Firm Reminds Investors of a Class Action ..
BU
06/18UPDATED DEADLINE MONDAY : ROSEN, SKILLED INVESTOR COUNSEL, Reminds Emergent BioS..
PR
06/17EMERGENT BIOSOLUTIONS 24 HOUR DEADLI : Former Louisiana Attorney General and Kah..
PR
06/17TWO DAYS LEFT TO ACTIVELY PARTICIPAT : Bronstein, Gewirtz & Grossman, LLC
BU
06/17KESSLER TOPAZ MELTZER & CHECKER, LLP : á Final Deadline Reminder for Emergent Bi..
BU
06/16DEADLINE ALERT : Bragar Eagel & Squire, P.C. Reminds Investors That a Class Acti..
BU
06/14EBS DEADLINE ALERT : Kessler Topaz Meltzer & Check, LLP Reminds Investors or Jun..
PR
06/14COVID-19 VACCINE JANSSEN : authorities in EU take steps to safeguard vaccine qua..
AQ
06/14JOHNSON & JOHNSONá : FDA Takes Steps to Increase Availability of COVID-19 Vaccin..
AQ
06/14JOHNSON & JOHNSONá : Statement on Supply of its Single-shot COVID-19 Vaccine
AQ
06/14NORTH AMERICAN MORNING BRIEFINGá : Stock Futures -2-
DJ
06/11Canada to Discard 300,000 Doses of J&J Covid-19 Vaccine
DJ
06/11Healthcare Shares Sink as Vaccine News Remains in Focus -- Health Care Roundu..
DJ
06/11EMERGENT BIOSOLUTIONSá : Gets FDA's Authorization for Two Batches of COVID-19 Va..
MT
06/11COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authori..
GL
More news
News in other languages on EMERGENT BIOSOLUTIONS INC.
05/28FDA und J&J vor Einigung über Wiederinbetriebnahme von Baltimore-Werk - Kreis..
04/20Produktion von Johnson & Johnson-Impfstoff in US-Werk nach Panne gestoppt
04/09Les valeurs à suivre vendredi 9 avril 2021 à Wall Street -
04/09JOHNSON & JOHNSONá : chute des livraisons de doses du vaccin la semaine prochain..
04/02FDA untersucht Qualitätsproblem bei Charge für J&J-Impfstoff - Kreise
More news
Analyst Recommendations on EMERGENT BIOSOLUTIONS INC.
More recommendations
Chart EMERGENT BIOSOLUTIONS INC.
Duration : Period :
Emergent BioSolutions Inc. Technical Analysis Chart | EBS | US29089Q1058 | MarketScreener
Technical analysis trends EMERGENT BIOSOLUTIONS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 86,00 $
Last Close Price 60,55 $
Spread / Highest target 98,2%
Spread / Average Target 42,0%
Spread / Lowest Target 5,70%
EPS Revisions
Managers and Directors
NameTitle
Robert G. Kramer President, Chief Executive Officer & Director
Richard Scott Lindahl Chief Financial Officer, Treasurer & Executive VP
Fuad El Hibri Executive Chairman
Sharon M. Solomon Chief Information Officer & Senior Vice President
Karen L. Smith Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
EMERGENT BIOSOLUTIONS INC.-32.42%3 245
JOHNSON & JOHNSON2.92%426 557
ROCHE HOLDING AG12.70%325 803
PFIZER, INC.5.43%217 246
NOVARTIS AG2.47%208 642
ABBVIE INC.5.57%199 795